Mike Brenner

Pharmacist, cardiology, dad/husband, sports, travel, and HIIT fan. My opinions are my own.

[Mike Brenner @MBrenner78]

@GBarnesMD @TODAYshow @alroker @isth @thrombosisday That’s great Geoff and definitely needed! Congrats!

[Mike Brenner @MBrenner78]

@konsiont @drpaulfriedman @MayoClinicCV @HRSonline Congrats Kostas!

[Yevgeniy Brailovsky DO MSc FACC @YevgeniyBr]

Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis
Fantastic effort by the writing committee! @MKIttlesonMD @fsheikh22 @MathewMaurer @frederickruberg @vsanchorawala
@JACCJournals: https://t.co/9hlV6kPx08

[Geoff Barnes @GBarnesMD]

The VA has long been a leader in #cvCoag care. See how rapidly they adopted a population health approach to #AntithromboticStewardship in this @CircOutcomes article. Thanks to @AHRQNews for funding! https://t.co/nengGSopT9

[Tom Cascino, MD @TomCascinoMD]

1/📌New Paper✏️
Prior work has shown convincingly that there are racial disparities in access to #LVAD and txp for pts with adv HF.  

We sought to understand if inequities exist among pts receiving care at expert centers & if pt preferences for care would impact disparities

[Mike Brenner @MBrenner78]

@GBarnesMD @UMich @UMichCardiology Congrats Geoff!

[Jonathan Davis, MD, MPHS @JonathanDavisHF]

Neither MRA nor SGLT2i will meaningfully impact BP in HF patients. They are not they reason your pt is hypotensive & can be safely started/used even at lower BP. Start #GDMTWorks & save lives! @gcfmd @AndrewJSauer @mvaduganathan @DrNasrien @dranulala @SJGreene_md @UCSFIMChiefs

[Tyler Larsen @TylerLarsenMD]

Amiodarone is an old anti-arrhythmic agent which means it can effect your LFTs, PFTs, and TFTs but not your NFTs because it's old and doesn't understand what they are.

[Mike Brenner @MBrenner78]

@StephDwyer21 @beaverspharmd @ACCinTouch @accpcardprn @JaclynneGowen This was at my son’s preschool awhile back. I should have quizzed them. Haha!

[Mike Brenner @MBrenner78]

@KNormanPharmD That’s fantastic!

[Mike Brenner @MBrenner78]

@DaveDixonPharmD So many issues here

[Mike Brenner @MBrenner78]

@muazzumshah @umichCVC @UMichCardiology @raklatch Congrats Muazzum! That’s great news!

[Mike Brenner @MBrenner78]

@wbaker0621 @robdeedo @sandersonrx @DaveDixonPharmD @joeymattingly @FinlaySchultz I’m next on the list at my local liquor store for a bottle at state minimum. It’s only been almost 2 years on this list.

[Raviele Antonio @drraviele]

SORT-AF RCT:
🩸Weight ⬇️ after AF ablation leads to signific ⬇️ in AF recurrence in pts with pers AF compared to pts with parox AF,
🩸but does not reduce AF burden in the entire study cohort
#Europace @PrashSanders @Dominik_Linz @SABOURETCardio @DrMarthaGulati @rafavidalperez

[Simon Dixon 🇳🇿 @SimonDixonMBChB]

Heart failure with preserved ejection fraction: a stepchild no more! | European Heart Journal | Oxford Academic https://t.co/WXfFj6MULt

[Jeremy Sussman @JeremySussman]

Excited to see our paper in Annals today looking at blood pressure control regiments by adding multiple low dose meds vs. maxing dose then starting new meds. 🧵 https://t.co/3d4L2nZO4v

[AmericanHeartJ @AmericanHeartJ]

In Press: Long-term Outcomes in Patients Treated with Flecainide for Atrial Fibrillation with Stable Coronary Artery Disease. https://t.co/LXZjFc276w

[Shaan Khurshid @shaan_khurshid]

Excited to share our new #afib #screening decision model in @JAHA_AHA! Simulating 50m US individuals aged ≥65 years, we found 10 #afib screening strategies--including #wearables--were effective & minimized false positives. A fun @MGHHeartHealth & @mgh_ita collaboration.

🧵⬇️

[Nature Reviews Cardiology @NatRevCardiol]

The STROKESTOP trial and The LOOP study used different approaches to screen for #AtrialFibrillation, with the aim of initiating oral anticoagulation to prevent stroke and death https://t.co/Tmkr7gXJ6W @EmmaSvennberg, @johanengdahl2

[إبراهيم الحربي Ibrahim Alharbi @Dr_ibrahimHarbi]

#ESC 2021 Trials Summary
#ESCCongress2021 #ESCCongress

https://t.co/cfKhblgxxy